 15. Use of an investigational drug within 30 days of randomization, or within 5 half-lives of the investigational drug the longer period will apply; investigational vaccines or biological agents e.g., the monoclonal antibody Synagis, may be granted exceptions through consultation with the principal investigator and GlaxoSmithKline. 